title: A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden.
abstract: Overall survival for glioblastoma patients is short. Standard treatment is surgery followed by radiochemotherapy and adjuvant temozolomide. The aim of this study was to evaluate the outcome for all patients with progressive disease treated with bevacizumab-based treatment combinations in the northern region of Sweden.
  
  
  
  This was a single-center retrospective analysis after bevacizumab-based second-line treatment for malignant glioma. All patients treated with bevacizumab, between 2007 and 2011 in our Center were retrospectively evaluated.
  
  
  
  Progression-free survival after the start of bevacizumab-based treatment was 20 weeks and overall survival was 31 weeks. Treatment was well tolerated, but 9% of patients (n=6) suffered from serious adverse events. In 68% of patients, a ≥25% decrease in contrast enhancement was seen at best response.
  
  
  
  Results from this retrospective study are comparable with earlier phase-II studies and motivate randomized trials of bevacizumab-based treatment in the second-line setting.
authors.affiliation: Department of Radiation Sciences, Oncology Umea University, Umea, Sweden maria.sandstrom@umu.se.
authors.forename: Maria
authors.initials: M
authors.lastname: Sandström
authors.affiliation: Department of Radiation Sciences, Oncology Umea University, Umea, Sweden.
authors.forename: Maria
authors.initials: M
authors.lastname: Laudius
authors.affiliation: Department of Radiation Sciences, Radiology Umea University, Umea, Sweden.
authors.forename: Thomas
authors.initials: T
authors.lastname: Lindqvist
authors.affiliation: Department of Radiation Sciences, Oncology Umea University, Umea, Sweden.
authors.forename: Thomas
authors.initials: T
authors.lastname: Asklund
authors.affiliation: Department of Radiation Sciences, Oncology Umea University, Umea, Sweden.
authors.forename: Mikael
authors.initials: M
authors.lastname: Johansson
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013548:Sweden
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Malignant glioma; anti-angionenesis treatment; bevacizumab